Galinpepimut-S
- Generic Name
- Galinpepimut-S
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- 12R66419FZ
- Associated Conditions
- -
- Associated Therapies
- -
Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS
- First Posted Date
- 2022-10-25
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Sellas Life Sciences Group
- Registration Number
- NCT05593185
Using a Targeted Cancer Vaccine (Galinpepimut-S) with Immunotherapy (Nivolumab) in Mesothelioma
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT04040231
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Cancer Center @ Commack, Commack, New York, United States
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Sellas Life Sciences Group
- Target Recruit Count
- 26
- Registration Number
- NCT03761914
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸St. Joseph Heritage Healthcare, Santa Rosa, California, United States
🇺🇸Innovative Clinical Research Institute (ICRI), Whittier, California, United States
WT1 Analog Peptide Vaccine in Patients With Multiple Myeloma Following Autologous Stem Cell Transplantation
Not Applicable
- Conditions
- Interventions
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Sellas Life Sciences Group
- Target Recruit Count
- 22
- Registration Number
- NCT01827137
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-12-24
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Sellas Life Sciences Group
- Target Recruit Count
- 22
- Registration Number
- NCT01266083
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath